The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The Battle with Insurance Companies to Obtain Prescriptions

The Battle with Insurance Companies to Obtain Prescriptions

March 17, 2018 • By Philip Seo, MD, MHS

  • Tweet
  • Email
Print-Friendly Version / Save PDF

We’ve all been there: You glance at your clinic schedule and see a name that gives you a feeling of dread, because you know you are failing the patient. Generally, these patients fall into one of two categories: Maintaining the patient’s remission requires an unconscionable amount of steroids, or the patient continues to relapse despite your best efforts. You know what you need to try next, but you are equally certain that it will be a battle, because the drug you have in mind is too new, too expensive or both. What do we do now?

You Might Also Like
  • Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies
  • PRACTICE PAGE: The ACR Takes on Insurance Companies
  • Two Years of Helping Patients Obtain Prescriptions
Explore This Issue
March 2018
Also By This Author
  • Drug Commercials—How Are They Still a Thing?

Sometimes, we lie. I know this because in 1999, Daniel Sulmasy conducted a study in which he contacted 471 randomly selected physicians and presented them with a number of hypothetical scenarios.1 With each scenario, participating physicians were asked if they would be willing to use incorrect or ambiguous documentation to ensure the patient would be able to obtain a procedure that he or she needed. Of the 169 physicians who responded to the survey, approximately half thought that some form of deception was justifiable if the patient required coronary bypass surgery, arterial revascularization or intravenous pain medications.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

We lie, but we feel guilty about lying. In Sulmasy’s study, a quarter of respondents indicated that deception was never justifiable. Of the physicians who thought that deception could be justified, many wrote long, free-text comments justifying that deception. One interesting theme emerged: physicians who worked in areas with high penetration of managed care markets were more likely to condone bending the truth. “This finding is consistent with the hypothesis,” Sulmasy writes, “that, as managed care brings more restrictions to a market, physicians practicing in that market become more willing to support deception as a means of circumventing these restrictions.”

The more things change, the more they remain the same. In 2013, the ACR’s Committee on Ethics surveyed members to identify ethical issues that affected rheumatologists. Not surprisingly, many of the respondents identified “embellishing coding … as a way to obtain medications who would otherwise not be covered by their insurance” as an important ethical issue.2 In fact, over half of respondents noted that “the high cost of treatment for patients” was the most common ethical issue that they encountered.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Ethics aside, the legal term for bending the truth to obtain a drug or a service for your patient is fraud. It also shouldn’t be necessary. Will Harvey, MD, MSc, member-at-large of the ACR’s Board of Directors, went to Washington on Feb. 7, 2018, to explain this to the U.S. Senate Special Committee on Aging.3 In his testimony, he explained truths that, to us, are self-evident:

Pages: 1 2 3 4 5 6 7 | Single Page

Filed Under: Legal, Legislation & Advocacy, Opinion, Pharma Co. News, Rheuminations Tagged With: drug benefits, pharmacy benefit managers, prescriptionIssue: March 2018

You Might Also Like:
  • Opinion: Insurance Companies Use Medically and Fiscally Irresponsible Formularies
  • PRACTICE PAGE: The ACR Takes on Insurance Companies
  • Two Years of Helping Patients Obtain Prescriptions
  • Are Insurance Companies’ Medication Directives Fiscally, Medically Questionable?

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)